Axsome Therapeutics Inc
(MIL:1AXSM)
€
214.7
-1.5 (-0.69%)
Market Cap: 11.06 Bil
Enterprise Value: 10.99 Bil
PE Ratio: 0
PB Ratio: 225.46
GF Score: 31/100 Axsome Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 19, 2026 / 05:35PM GMT
Release Date Price:
€195.25
Leonid Timashev
RBC Capital Markets Inc - Equity Analyst
All right. Thanks, everyone, for being here. Happy to have our first session after our keynote and lunch here with Axone, represented by Mark Jacobson and Nick Pizzie. So thanks for being here.
Mark Jacobson Axsome Therapeutics Inc;Chief Operating Officer
Thanks for having us. Yeah, we're happy to be here. Thanks, Leo.
Questions & Answers
Leonid Timashev
RBC Capital Markets Inc - Equity Analyst
Great. So a lot of exciting developments lately with the company. So there's a lot to talk about, but maybe we can start off with the approval in Alzheimer's agitation recently came through. Maybe just by way of introduction, you can sort of remind us of.
Differentiation the drug offers and maybe weaving in now that you have a label, sort of how that met or exceeded your expectations and how you're feeling about that going forward.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot